Purpose: To investigate the long-term prognosis and prognostic patterns of epilepsy in a single practice study from a developing country. Methods: Consecutive patients first seen in an epilepsy clinic in Cairo, Egypt between January 1994 and December 2009 with at least 4 years of follow-up were included. Demographic, clinical, EEG and imaging findings at diagnosis were recorded. At follow-up, treatment was adjusted as clinically indicated. The response to the first drug was defined as 6-month seizure remission. Outcome measures included 2-year remission (R) and 2-year sustained remission (SR). Prognostic patterns were early (ER) and late remission (LR), relapsing-remitting (RR) course, worsening course (WC) and no remission. Results: Included were 287 patients aged 1-66 years and followed for 2237.0 person-years (mean 7.8 years). 244 (85%) attained 2-year R. The cumulative time dependent probability of R was 86.7% at 10 years. Only the response to the first drug predicted R. 82 (28.6%) attained 2-year SR. The probability of SR was 40.9% at 10 years. Poor treatment response and nocturnal seizures predicted lowered SR. R and SR were inversely correlated to the number of drugs. 208 patients (72.5%) entered ER, 36 (12.5%) entered LR, 138 (48.1%) had RR course. A WC was present in 24 (8.4%), 43 (15.0%) never entered remission. Prognostic patterns varied with neurological examination, MRI findings, pre-treatment seizure frequency, seizure type, number of seizure types, etiology, syndrome and response to first drug. Conclusions: The long-term prognosis of newly diagnosed epilepsy patients from a developing country is in keeping with published reports.
Introduction
Epilepsy is a chronic neurological condition representing a significant burden for the patient and the society [1] . Although epilepsy is treatable, little is known on the long-term prognosis of the disease. Epidemiologic studies from Europe and North America indicate that up to 95% of patients with newly diagnosed epilepsy achieve at least 1-year seizure remission at some time after the onset of the disease [2] [3] [4] [5] [6] [7] [8] [9] and up to 71% are in remission at last observation with or without drugs [2] [3] [4] [9] [10] [11] . However, studies in European and US populations have investigated the timing and outcome of prolonged periods of seizure freedom (the so called prognostic patterns) [2] [3] [4] [10] [11] [12] [13] [14] . These studies have shown that early remission predicts long-term remission. However, some patients enter remission during the course of the disease while others experiencing early remission may relapse and eventually fail to achieve further remission or may again become seizure-free. These different outcomes show that the long-term prognosis of epilepsy is variable and not always predicted by the response to the first treatment. To our knowledge, these findings have been confirmed by only one study done outside of Europe and North America [15] and there are no reports on the long-term prognosis of epilepsy in newly diagnosed patients from developing countries.
As the efficacy and tolerability of antiepileptic drugs is genetically determined [16] [17] [18] , the prognosis of epilepsy may vary according to the genetic and ethnic profile of the affected individuals.
On this background, the main purposes of the present study were to investigate the long-term prognosis of epilepsy and define the temporal patterns of seizure outcome in a cohort of newly diagnosed patients seen in a single center in Greater Cairo in Egypt, a developing country, from the time of the diagnosis and followed for a prolonged period of time.
Materials and methods

Setting and patients
This is a retrospective cohort study of patients with epilepsy firstly seen by a single senior epileptologist (HH) in the Epiclue epilepsy clinic, a tertiary health facility serving mostly Greater Cairo, which includes the capital and its province in Egypt, The city is the largest urban area in Africa and ranks number 17 among the largest cities in the world as regard population, with 15.6 million people in 2016.
In Egypt, in the absence of a strong primary physician system, there are two parallel heath care systems, governmental and private. Private clinics are easier to access than waiting for referral to a neurologist. Patients are aware that seizures fall in the domain of the neurologists and for this reason they seek medical advice directly from the neurologists both in the pediatric and adult population. Our institution has been a specialized private epilepsy clinic since 1994, gaining reputation all over Egypt and in neighboring countries. The clinic receives both newly diagnosed and referred patients.
Enrolled were consecutive patients who had their first visit in the clinic between January 1994 and December 2009 and were followed up until date of last observation or January 2014, whichever came first. To be included in the study, a patient must have had recurrent unprovoked seizures, an epilepsy syndrome or a single unprovoked seizure with high probability of recurrence (generally, a structural lesion and/or EEG epileptiform abnormalities)" [19] , be untreated at the time of diagnosis, and have at least 4 years of follow up. A patient was excluded if (s)he had only acute symptomatic seizures "clinical seizure occurring at the time of a documented systemic insult or in close temporal association with a documented brain insult" [20] .
During the first visit, the senior epileptologist collected the medical history and seizure details from the patients and any witnesses, by using a structured questionnaire. Neurological examination and mental status assessment (based on patient's interview and history of academic or social achievements) were performed in all patients. A standard awake interictal EEG was performed in all cases, whereas a sleep EEG and/or a video-EEG were performed only when clinically indicated. Magnetic resonance imaging (MRI) was performed in patients diagnosed with focal epilepsy by semiology or EEG. All other patients underwent brain computer tomography (CT).
Patients were compliant with follow up visits, scheduled every 3-6 months or earlier, if clinically indicated.
Treatment
Monotherapy was the first antiepileptic drug (AED) regimen in all cases. The choice of the drug was made on account of the indication, the patient's personal characteristics (child, woman of childbearing potential, elderly), the tolerability profile, the patient's socio-economic status, and the potential for drug interactions (in patients receiving drugs for other clinical conditions). The first maintenance dose was preferably in the lowest effective dose, except for patients with benign childhood epilepsies (rolandic or occipital epilepsy) in whom just reassurance or, if required, a low dose (approximately half of the recommended dose) was purposefully administrated.
In patients relapsing with the first maintenance dose, further increases were attempted to achieve seizure control or up to the highest tolerated dose, whichever came first. When the first monotherapy failed, a second regimen could be another drug given as alternative monotherapy or an adjunctive therapy based on the presence of single or multiple seizure types and the overall disease severity. Treatment was changed to another drug if the patient had an idiosyncratic reaction or intolerable side effects.
At each follow up visit, seizure frequency, AED daily doses, and compliance were routinely recorded (by history or AED serum levels), with treatment adjustments as dictated by the clinical circumstances.
For each case, a number of variables were searched and noted in ad-hoc case-record forms and the following were collected for the purposes of this study: Epilepsy syndrome, sex, status epilepticus, history of febrile convulsions, family history of epilepsy, age of onset of seizures, disease duration at diagnosis, pre-treatment seizure frequency, number and type of seizures, presence of nocturnal seizures, etiology, first EEG record, MRI/CT findings, neurological and mental examination, first AED used, response to initial monotherapy, and number of AEDs tried until seizure remission (if achieved).
Definitions
Epilepsy syndromes were defined according to the 1989 recommendations of the International League Against Epilepsy (ILAE) [21] and classified in broad categories. Seizure types were classified according to the 1981 ILAE definitions [22] and grouped as focal or generalized. Epileptiform discharges in the first EEG was a prerequisite for the diagnosis of well known epilepsy syndromes, like idiopathic generalized epilepsies and Rolandic epilepsy. Status epilepticus (a seizure or a flurry of seizures lasting more than 30 minutes), if present, was coded separately. History of febrile convulsions was recorded when present. Family history of seizures was also collected and considered positive when epilepsy was present in first degree relatives (i.e., parents, siblings and offspring). Age at onset of seizures (excluding febrile seizures) was noted and grouped in the following categories: 5 years, 6-15 years, 16-29 years, 30-59 years and 60 years or older. Disease duration at diagnosis was noted and categorized as <1 year; 1 year. Pre-treatment seizures were counted and indicated in categories (<6, 6). Nocturnal seizures were seizures occurring during sleep. Etiology was classified as idiopathic, cryptogenic or symptomatic. The first EEG record was defined as normal, slow or epileptiform (with or without slow waves). Neurological examination and mental status were coded as normal or abnormal according to clinical judgment. The first AED included carbamazepine, valproate, phenobarbital, phenytoin, vigabatrin, lamotrigine, oxcarbazepine, topiramate and ethosuximide. The AEDs used during the disease course were counted and coded as 1, 2, 3, 4, 5 or more.
A period of remission was defined as two or more years of complete seizure control after the diagnosis of epilepsy.
Early remission was defined as a 2-year remission period started immediately or within the first 2 years after diagnosis of epilepsy with or without relapses.
Late remission was defined as a 2-year remission period achieved at least 2 years after diagnosis of epilepsy with or without relapses.
Sustained remission was defined as a 2-year remission started at any time after diagnosis (early sustained remission or late sustained remission) and persisting until the last follow-up visit (Remitting course).
Relapse was the occurrence of seizures after one or more periods of remission (Relapsing-remitting course or, if not in remission at last follow-up, Worsening course).
Terminal remission was defined as a 2-year remission at the last follow-up visit, with (Relapsing-remitting course) or without (Remitting course) previous relapses. Breakthrough seizures were not counted as a relapse if there was non adherence to the assigned treatment and return to seizure freedom after resumption of the medication.
No remission was defined as no 2-year remission through the entire follow-up period.
Good response to the first AED was the achievement of at least 6 months seizure remission after treatment start.
Statistical analysis
Data was summarized using range, mean, standard deviation and median with interquartile range (IQR) for quantitative variables or frequency and percentages for qualitative variables. Comparison between groups was performed using the Student's t-test for independent samples, or the Mann-Whitney test as appropriate, for continuous variables and the Chi square or (when one or more categories had expected counts less than 5) the Fisher's exact test for categorical variables. The cumulative timedependent probability to achieve 2-year remission and 2-year sustained remission was calculated using Kaplan-Meier curves comparing the demographic and clinical features at diagnosis, using the Log-rank test. Independent predictors of 2-year remission (ever and sustained) were identified using the Cox proportional hazards function. The variables included in the models were those found significant on univariate analysis. Risks were expressed as hazards ratios (HRs) and adjusted HRs (adj HRs) with 95% confidence intervals (CIs). Statistical significance was set at the 5% level (p = 0.05). All analyses were performed with SAS (version 9.2; SAS Institute, Inc., Cary, NC, USA).
Results
During the study period, a total of 642 newly diagnosed patients were referred to the clinic. Three hundred fifty-five (55.3%) were excluded for having less than 4 years of follow-up. Included were 287 patients (161 men and 126 women) with a mean (standard deviation, SD) age at diagnosis of 15.6 (11.5) years (median 13 years; range 1-66 years). Excluded were 219 men and 136 women aged 1-79 years; mean age at diagnosis, 19.8 (17.3) years (median 13 years). Included and excluded patients did not differ according to sex (p = 0.15) and median age at diagnosis (p = 0.10). The general characteristics of the sample are illustrated in Table 1 . 277 (96.5%) patients were inhabitants of Greater Cairo while only 10 patients came from other governerates. Men were slightly predominant and children aged 15 years or younger accounted for two-thirds of cases. The mean age at onset of seizures (with standard deviation, SD) was 14.7 years (11.3) and the mean disease duration was 0.8 years (2.0) (range 0-17). Disease duration at diagnosis was less than one year in two-thirds of cases (Table 1) . Family history of epilepsy was present in less than 10% of cases and history of febrile seizures was even less common. One third of patients experienced nocturnal seizures. Focal seizures were slightly predominant while status epilepticus was rarely reported. Almost one-half of cases reported 2 or more seizure types. One out of ten patients experienced only one unprovoked seizure at diagnosis and more than half had 6+ seizures. Interictal epileptiform discharges were detected in more than 70% of cases in the first EEG record. The tracing was normal in one-fifth of cases. An abnormal MRI/CT was present in 13% of cases and an etiologic factor was detected in 11% (the commonest being mesial temporal sclerosis, stroke and cortical dysplasia). The commonest epilepsy syndromes were, in decreasing order, cryptogenic focal epilepsy, juvenile myoclonic epilepsy, symptomatic focal epilepsy, juvenile absence epilepsy and idiopathic focal epilepsy that accounted for more than 80% of cases. Valproate was the commonest first-choice drug (almost half of cases), followed by carbamazepine and oxcarbazepine. Only three patients were left untreated at diagnosis.
The study cohort was followed for 2237.0 person-years; the mean (SD) follow-up was 7.8 (3.6) years (range 4-20 years). During follow-up a total of 244 patients (85%) attained remission. The cumulative time dependent probability of remission was 72.1% at 1 year from the diagnosis, 75.3% at 2 years, 83.6% at 5 years, and 86.7% at 10 years (Fig. 1A) . The median (IQR) time to remission was 3 (0-24) months. Remission was affected by neurological examination, MRI/CT findings, etiology, pre-treatment seizure frequency, number of drugs taken, and response to the first AED (Table 2 ), but multivariate analysis confirmed only treatment response as an independent predictor of remission (Table 3) . Compared to patients successfully treated, those with poor response to the first drug had an adjHR of 0.14 (95% CI 0.08-0.24). When response to the first AED was removed from the model, pre-treatment seizure frequency attained significance. Compared to patients diagnosed at the time of the first seizure, the adjHR was 0.91 (95% CI 0.60-1.37) in those seen after 2-5 seizures, and 0.64 (95% CI 0.43-0.96) in those seen after 6+ seizures. A total of 82 patients (28.6%) attained sustained remission (remitting course). The cumulative time dependent probability of sustained remission was 29.4% at 1 year from the diagnosis, 32.9% at 2 years, 40.9% at 5 and 10 years (Fig. 1B) . Within 9 months, 25% of patients had started a sustained remission. Sustained remission was affected by neurological examination, MRI/CT findings, family history of epilepsy, nocturnal seizures, pre-treatment seizure frequency, number of seizure types, etiology, number of drugs taken, and response to the first AED (Table 2 ), but only poor treatment response and presence of nocturnal seizures were independent predictors of lower chance of sustained remission (Table 3) . When response to the first AED was removed from the model, only nocturnal seizures attained significance. The cumulative time dependent probability of remission and sustained remission varied significantly in function of the number of drugs used during the entire follow-up period: the higher the number of drugs used, the lower the probability of remission (Fig. S1A ) and sustained remission (Fig. S1B) .
Two hundred and eight patients (72.5%) entered early remission but only 71 (24.7%) were in terminal remission (Fig. 2) . Thirty-six patients (12.5%) entered late remission and 11 (3.8%) were in terminal remission. In total, 138 patients with early or late remission followed by a relapse (48.1%) were in terminal remission. A worsening course (early or late remission but no remission at last follow-up) was present in 24 cases (8.4%). Forty-three patients (15.0%) never entered remission. Prognostic patterns varied according to selected clinical variables at the time of diagnosis (Table 4) [2-4,9-15]. Significant differences were found for neurological examination, mental status, MRI findings, pre-treatment seizure frequency, seizure type, number of seizure types, etiology, syndrome and response to the first AED. Although the relapsing-remitting course Fig. 1 . Cumulative probability of starting a 2-year remission/2-year sustained remission in the study cohort. GC/GS = generalized symptomatic/cryptogenic; GI = generalized idiopathic; FC = focal cryptogenic; FI = focal idiopathic; FS = focal symptomatic; EEG = electroencephalogram; MRI = magnetic resonance imaging; AED = antiepileptic drug. na* = not available; the cumulative probability could not be estimated because there were no patients at risk in this category at this time point. MRI = magnetic resonance imaging; CT = computerized tomography; AED = antiepileptic drugs; HR = hazard ratio; adjHR = adjusted hazards ratio; 95% CI = confidence interval. na = not available; the variable was not included in multivariable analysis (not significant in univariable analysis); na* = not available; no patients in this category achieved a 2-year sustained remission. predominated in all syndromic categories, a worsening course and the absence of remission were more frequent in focal epilepsies than in generalized epilepsies (Table S1 ).
Discussion
Based on our findings, the long-term prognosis of newly diagnosed epilepsy in patients from a single practice study in a developing country roughly overlaps the predominantly favorable outlook of the disease already documented in published reports. At ten years, the cumulative probably of attaining 2-year remission of seizures was 86.7% and the probability of sustained remission was 40.9%. After five years, the probability to achieve remission became negligible. As several newer generation AEDs were not used for the high cost (to be sustained by the patient and the family), the similarity of our results with those of countries where new generation drugs were available suggest the low potential for improvement by the inclusion of these compounds.
The response to the first AED was the only factor associated with remission, when adjusting for variables of prognostic significance like etiology, pre-treatment seizure frequency, and epilepsy syndrome. A good response to the first drug (indicated here by the achievement of at least six months of seizure remission immediately after treatment start) has been confirmed by others as a prognostic predictor [11, 12, 14] . When the first drug failed, a second drug was associated with a lower probability of remission. Seizure control was increasingly lower after inclusion of additional drugs in the therapeutic scheme. Our findings are in line with other reports [11, 14, 15] . Treatment response can be considered a marker of a low disease severity rather than the effect of a timely therapeutic intervention, as the effects of treatment are independent from the number of seizures experienced prior to treatment start [23] and high remission rates can be found even in untreated or largely untreated patients with epilepsy [8, 24] . The presence of a structural lesion and other markers of disease severity, which were found by univariate analysis to be associated with a reduced chance of remission, lost significance after adjustment. The small numbers can explain at least in part our findings.
A higher pre-treatment seizure frequency, here a predictor of remission when not adjusting for treatment response, has been repeatedly associated with a more severe outcome and a lower chance of remission [9, 25] and can be again explained by the intrinsic severity of the disease.
Nocturnal seizures have been found to predict a lower chance of sustained remission. Patients with a first nocturnal seizure are at increased risk of relapse [26] . This may reflect an increased susceptibility to experience recurrent seizures. A poor compliance with treatment in patients with nocturnal seizures, that by definition have a lower impact on daily life activities, is another possible explanation.
The first interictal EEG showed epileptiform discharges in 71% of cases. This finding may be a reflection of the predominance of pediatric epilepsy syndromes in our cohort. Previous studies showed that the proportion of cases with epileptiform activity in the first EEG was significantly greater in children than in adults both in prospective (59% versus 39%) [27] and in retrospective series [28] .
The lack of association between remission and epilepsy syndromes is worth noting. The use of broad syndromic categories (including epilepsies with differing propensity to respond to the available treatments) is a possible explanation.
Almost three-fourths of our patients entered early remission and one-eighth entered late remission; however, in more than one half of cases remission was followed by a relapse. These findings are difficult to compare with other reports, as the periods of remission and the definitions of the patterns differ (Table 4) [2] [3] [4] [9] [10] [11] [12] [13] [14] [15] . Remission followed by relapse was observed in 6% of people in the Rochester, Minnesota cohort [2] . The longer follow-up in that study is a possible explanation for the shift of several patients from a relapsing-remitting pattern to terminal remission. A more detailed distribution of prognostic patterns has been used in a study which followed 516 children with epilepsy for 10+ years and identified eight seizure patterns ranging from early 1-year remission, no relapse and complete remission at last follow-up (33%) to never achieving 1-year remission (5%) [4] . The shorter period of remission (1-year vs. 2-year in our study) may explain at least in part the higher rates of individuals with early remission and the lower rates of people never achieving remission.
Better outcomes were reported by studies done in children [9, 11] . The longer follow-up and the inclusion of benign epilepsy syndromes with onset in childhood are possible explanations.
With one exception [3] , in line with us several authors [11, 14, 15] showed early remission prevailing on late remission. This can be explained by the progressive decline in the likelihood of seizure freedom with successive AED regimens.
A worsening course was found in less than 10% of cases, in line with a Dutch study in children [11] . The higher proportions found by others can be explained by the inclusion of patients with three or more unprovoked seizures at diagnosis [3] or by the short follow-up [15] .
Only one-sixth of our patients never entered remission. With one exception [9] , the percentage of patients with newly diagnosed epilepsy never entering 2-year or 5-year remission ranged from 10 to 25% [2, 3, [10] [11] [12] . As the follow-up varied significantly across studies (see Table 4 ) [2] [3] [4] [9] [10] [11] [12] [13] [14] [15] , an explanation of these fairly consistent findings is that the chance of remission in a patient with a long history of seizure recurrence is virtually absent. In contrast with patients not experiencing remission periods, the percentage of cases with relapsing-remitting seizures varies significantly according to the length of follow-up, being low in studies with brief follow-up periods, tending to increase with the length of the observation, and to decrease thereafter. Patients with a relapsing-remitting course were the largest proportion of our cases. This may reflect the relatively short follow-up. We cannot thus exclude that with prolonged observation several of these patients can achieve terminal remission. The probability also exists that some patients with mild, self-remitting epilepsy syndromes were excluded for having shorter follow-up, leaving in the study patients with persisting seizures.
The study has limitations, this was a retrospective survey done in a prevalent cohort. It is not a population-based study, there may have been a referral bias for those seen in our epilepsy clinic. The length of follow-up varied across patients and, even if the use of Kaplan-Meier curves accounted for the duration of the clinical observation for the calculation of the chance of remission, prognostic patterns may vary with time. We did not adopt specific measures to control patients' compliance with treatment. To the best of our knowledge, however we did not count breakthrough seizures due to non-adherence to the assigned treatment. Finally, the patients had access to a limited number of drugs and, although we do not expect better outcomes with newer generation compounds, we cannot exclude that long-term prognosis and prognostic patterns might vary with the number and type of AEDs used.
In conclusion, the high potential of epilepsy to recover with time is also confirmed in a study done in a developing country, where the access to the entire armamentarium of AEDs was limited. The response to the first drug is by and large the best predictor of remission and sustained remission. However, the study may not be sufficiently powered for other markers of disease severity to become prognostic predictors. About half of the study population presents a relapsing-remitting pattern and, in this regard, an unpredictable prognosis with reference to complete and sustained seizure control. In addition, prognostic patterns vary with a number of markers of disease severity and treatment response.
Selection bias and the relative short follow-up can explain the high proportion of patients with prolonged periods of remission but still at risk of relapse. As anticipated by several reports with longer follow-up [2, 4, 9, 11, 14] , we expect that an increasing number of patients now falling in the relapsing-remitting pattern will definitely achieve terminal remission. The proportion of patients never experiencing prolonged periods of remission is fairly low and is in line with several others (see Table 4 ) [2] [3] [4] [9] [10] [11] [12] [13] [14] [15] confirming that true drug resistance is generally present in less than one fourth of cases.
